Mycobacterial virulence: impact on immunogenicity and vaccine research [version 1; peer review: 4 approved]
The borderline between virulence and efficacy in live attenuated vaccine strains is often blurred and this is also the case for the Bacillus Calmette–Guérin (BCG), the only currently licensed anti-tuberculosis vaccine used on a large, global scale, which was obtained almost 100 years ago. While BCG...
Main Authors: | Vera M. Kroesen, Jan Madacki, Wafa Frigui, Fadel Sayes, Roland Brosch |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2019-11-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/8-2025/v1 |
Similar Items
-
Genomic and phenotypic characterization of Mycobacterium tuberculosis’ closest-related non-tuberculous mycobacteria
by: Camille Sous, et al.
Published: (2024-06-01) -
Recent advances in nontuberculous mycobacterial lung infections [version 1; peer review: 2 approved]
by: David Horne, et al.
Published: (2019-10-01) -
Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection
by: Matthias I. Gröschel, et al.
Published: (2017-03-01) -
Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus.
by: Fabienne Ripoll, et al.
Published: (2009-06-01) -
RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection.
by: Louis S Ates, et al.
Published: (2018-06-01)